StockData

Biodesix vs MDxHealth

BDSX and MDXH side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BDSX and MDXH compare

Biodesix grew revenue faster over the last twelve months (34.5% versus 19.8% for MDxHealth).

Biodesix keeps more of each dollar of sales as profit, with a net margin of −27.0% compared with −31.1% at MDxHealth.

MDxHealth scores higher on the StockData Score (5 against 4 for Biodesix), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBDSXMDXH
Size and price
Market cap$93.7M–
Share price$8.88$0.149
Change, 1 year11.0%−95.9%
Change, 5 years−93.4%−98.4%
Beta (5Y)1.723.13
Employees334364
StockData Score
Total score45 (better)
Valuation score00
Growth score23 (better)
Performance score11
Health score11
Dividend score00
Valuation
P/S0.9×–
P/B10.2×–
FCF yield−21.6%–
Growth
Revenue growth (TTM)34.5% (better)19.8%
Revenue growth, 5Y average14.2%42.3% (better)
Profitability
Gross margin–64.5%
Operating margin−20.0%−13.4% (better)
Net margin−27.0% (better)−31.1%
FCF margin−19.7%−3.1% (better)
Return on equity−540%–
Return on invested capital−61.4%–
Financial health
Debt / equity5.12–
Interest coverage−2.5×−0.6× (better)
Current ratio2.85 (better)1.08
Altman Z-score−6.16–
Piotroski F-score33
Dividends and buybacks
Shareholder yield0.00%–
Ownership
Held by institutions41.4%32.3%
Insider net buying, 12 months$4.0M (better)$991K

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.